AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33986477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 32448782 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 150
Study 32448782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 150
Study 32448782 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) and Tacrolimus (TAC)
Number of subjects: 150
Study 35090087 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% non-alcoholic chlorhexidine (CHX)
Number of subjects: 60
Study 35090087 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% saline rinses (NaCl)
Number of subjects: 60
Study 35090087 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal mouthwash (MW)
Number of subjects: 60
Study 35090087 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (H2O)
Number of subjects: 60
Study 33432167 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BNT) injections
Number of subjects: 100
Study 33432167 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention (bimedial rectus muscle recession)
Number of subjects: 100
Study 33751774 — intervention group
Group type: EXPERIMENTAL
Intervention: VisioCyt test
Number of subjects: 1360
Study 33689989 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial hip musculature strengthening (AMHG)
Number of subjects: 52
Study 33689989 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral hip musculature strengthening (PLHG)
Number of subjects: 52
Study 33629751 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Habits (CBM intervention)
Number of subjects: 40
Study 33629751 — intervention group
Group type: COMPARATOR
Intervention: Symptom Tracking (Control)
Number of subjects: 40
Study 32986235 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloons
Number of subjects: 0
Study 32986235 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 0
Study 34308814 — intervention group
Group type: COMPARATOR
Intervention: Yoga
Number of subjects: 0
Study 34308814 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Support System (MSS) training
Number of subjects: 0
Study 34308814 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT)
Number of subjects: 0
Study 34308814 — intervention group
Group type: COMPARATOR
Intervention: Peer support group (SG)
Number of subjects: 0
Study 34308814 — intervention group
Group type: COMPARATOR
Intervention: Wellness education (WE)
Number of subjects: 0
Study 34798475 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary teaching with creativity training for Group 2 (teaching assistants, n = 30)
Number of subjects: 191
Study 34798475 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary teaching for Group 1 (typical students, n = 80)
Number of subjects: 191
Study 34798475 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 81) taught by nursing faculty only, without creativity training
Number of subjects: 191
Study 33881402 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutically purposeful use of smartphone
Number of subjects: 118
Study 33881402 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational use by the physiotherapist
Number of subjects: 118
Study 33881402 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational use by the patient
Number of subjects: 118
Study 33881402 — intervention group
Group type: COMPARATOR
Intervention: No smartphone use (control condition)
Number of subjects: 118
Study 32057627 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand massage
Number of subjects: 90
Study 32057627 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage
Number of subjects: 90
Study 32057627 — intervention group
Group type: COMPARATOR
Intervention: Placebo massage
Number of subjects: 90
Study 34523382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised dexmedetomidine 2 μg/kg (group D)
Number of subjects: 71
Study 34523382 — intervention group
Group type: COMPARATOR
Intervention: Nebulised ketamine 2 mg/kg (group K)
Number of subjects: 71
Study 32866050 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% silver nitrate (AgNO3) solution followed by 5% sodium fluoride (NaF) varnish without fTCP
Number of subjects: 408
Study 32866050 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% silver nitrate (AgNO3) solution followed by 5% sodium fluoride (NaF) varnish with functionalized tricalcium phosphate (fTCP)
Number of subjects: 408
Study 35099659 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal-tDCS
Number of subjects: 39
Study 35099659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal-tDCS
Number of subjects: 39
Study 35099659 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 39
Study 35099659 — intervention group
Group type: COMPARATOR
Intervention: No-tDCS
Number of subjects: 39
Study 33191181 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 30
Study 33191181 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 30
Study 35394807 — intervention group
Group type: COMPARATOR
Intervention: Education arm
Number of subjects: 461
Study 35394807 — intervention group
Group type: COMPARATOR
Intervention: Air filtration arm
Number of subjects: 461
Study 35394807 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-response analysis
Number of subjects: 461
Study 34181770 — intervention group
Group type: EXPERIMENTAL
Intervention: HVPG measurement after intervention
Number of subjects: 289
Study 34181770 — intervention group
Group type: COMPARATOR
Intervention: HVPG measurement in compensated cirrhosis
Number of subjects: 289
Study 34181770 — intervention group
Group type: COMPARATOR
Intervention: HVPG measurement in decompensated cirrhosis
Number of subjects: 289
Study 34181770 — intervention group
Group type: COMPARATOR
Intervention: HVPG measurement in alcohol-associated cirrhosis
Number of subjects: 289
Study 34181770 — intervention group
Group type: COMPARATOR
Intervention: HVPG measurement in unicentric trials
Number of subjects: 289
Study 34181770 — intervention group
Group type: EXPERIMENTAL
Intervention: Smallest detectable difference in HVPG
Number of subjects: 289
Study 34578906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol supplementation (CBD)
Number of subjects: 21
Study 34578906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 33318104 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour simulation-based training session
Number of subjects: 57
Study 33318104 — intervention group
Group type: COMPARATOR
Intervention: Wait list control condition
Number of subjects: 57
Study 36238481 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum M-CSF
Number of subjects: 60
Study 36238481 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TIMP-1
Number of subjects: 60
Study 36238481 — intervention group
Group type: COMPARATOR
Intervention: Serum CER
Number of subjects: 60
Study 36238481 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of M-CSF, CER, TIMP-1, HA, PC-III, C-IV, and LN
Number of subjects: 60
Study 36238481 — intervention group
Group type: EXPERIMENTAL
Intervention: M-CSF, TIMP-1, LN, HA, C-IV, and PC-III levels
Number of subjects: 60
Study 36238481 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of liver fibrosis with serum M-CSF, PC-III, TIMP-1, HA, LN, and C-IV levels
Number of subjects: 60
Study 36238481 — intervention group
Group type: COMPARATOR
Intervention: Correlation of liver fibrosis with serum CER
Number of subjects: 60
Study 36238481 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic usefulness of M-CSF, CER, and TIMP-1
Number of subjects: 60
Study 32174356 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative auditory cues on timing and direction of upcoming motion
Number of subjects: 20
Study 32174356 — intervention group
Group type: COMPARATOR
Intervention: Non-informative auditory cues
Number of subjects: 20
Study 35717771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness (cognitive approach)
Number of subjects: 121
Study 35717771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep education
Number of subjects: 121
Study 35717771 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 121
Study 32222929 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL) assessment using SF-36 tool
Number of subjects: 500
Study 34020153 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (EX)
Number of subjects: 35
Study 34020153 — intervention group
Group type: COMPARATOR
Intervention: Light-intensity exercise control (CON)
Number of subjects: 35
Study 32813928 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal hypopressive technique (AHT)
Number of subjects: 0
Study 32813928 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 0
Study 33612294 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic endovascular aortic repair for complicated acute type B aortic dissections
Number of subjects: 172
Study 33612294 — intervention group
Group type: COMPARATOR
Intervention: Thoracic endovascular aortic repair for uncomplicated acute type B aortic dissections
Number of subjects: 172
Study 33612294 — intervention group
Group type: COMPARATOR
Intervention: Complicated type B aortic dissections
Number of subjects: 172
Study 33612294 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated acute type B aortic dissections
Number of subjects: 172
Study 33191450 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus S-1 (nab-P/S)
Number of subjects: 110
Study 33191450 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel plus gemcitabine (nab-P/G)
Number of subjects: 110
Study 32926799 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuma longa extract (CL)
Number of subjects: 70
Study 32926799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 34600554 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative immunonutrition
Number of subjects: 164
Study 34600554 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition
Number of subjects: 164
Study 34600554 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D-3L
Number of subjects: 164
Study 34600554 — intervention group
Group type: EXPERIMENTAL
Intervention: QLU-C10D
Number of subjects: 164
Study 34600554 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D-3L anxiety
Number of subjects: 164
Study 34600554 — intervention group
Group type: EXPERIMENTAL
Intervention: Utility scores
Number of subjects: 164
Study 33232476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib 100 mg once per day
Number of subjects: 161
Study 33232476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib 100 mg twice per day
Number of subjects: 161
Study 33232476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib 200 mg twice per day
Number of subjects: 161
Study 34698889 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (37.9% of participants)
Number of subjects: 5981
Study 34698889 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (29.6% of participants)
Number of subjects: 5981
Study 34698889 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (25.5% of participants)
Number of subjects: 5981
Study 34698889 — intervention group
Group type: EXPERIMENTAL
Intervention: Other statins (7.0%, predominantly pravastatin)
Number of subjects: 5981
Study 34698889 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency statins (atorvastatin and rosuvastatin)
Number of subjects: 5981
Study 34698889 — intervention group
Group type: COMPARATOR
Intervention: Low-/moderate-potency statins
Number of subjects: 5981
Study 33716071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous hysteropexy with graft
Number of subjects: 183
Study 33716071 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral ligament suspension
Number of subjects: 183
Study 32827835 — intervention group
Group type: EXPERIMENTAL
Intervention: 4vHPV vaccine
Number of subjects: 1128
Study 32827835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1128
Study 35568261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond PRINEO
Number of subjects: 54
Study 35568261 — intervention group
Group type: EXPERIMENTAL
Intervention: Staples
Number of subjects: 54
Study 35568261 — intervention group
Group type: COMPARATOR
Intervention: Dermabond
Number of subjects: 54
Study 34929410 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-day course of antibiotics
Number of subjects: 0
Study 34929410 — intervention group
Group type: COMPARATOR
Intervention: Fourteen-day course of antibiotics
Number of subjects: 0
Study 36153529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensuring the availability of influenza vaccine supply
Number of subjects: 0
Study 36153529 — intervention group
Group type: EXPERIMENTAL
Intervention: Developing influenza vaccine awareness
Number of subjects: 0
Study 36153529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ensuring influenza vaccine supply and developing influenza vaccine awareness
Number of subjects: 0
Study 36153529 — intervention group
Group type: COMPARATOR
Intervention: Control arm with no intervention
Number of subjects: 0
Study 35724670 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg plus FDCSL (400/90 mg)
Number of subjects: 12
Study 35724670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg plus FDCSL (400/90 mg)
Number of subjects: 12
Study 35724670 — intervention group
Group type: COMPARATOR
Intervention: FDCSL (400/90 mg) alone
Number of subjects: 12
Study 32302321 — intervention group
Group type: EXPERIMENTAL
Intervention: High transparency modification in Experiment 2
Number of subjects: 0
Study 32302321 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard financial aid allocation task in Experiment 1
Number of subjects: 0
Study 35085455 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent, family-based intervention including parent group sessions, home nursing visits, and multidisciplinary clinical encounters.
Number of subjects: 11
Study 35085455 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 11
Study 35085455 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent focus groups (qualitative assessment).
Number of subjects: 11
Study 35085455 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual factors identified by healthcare providers (HCPs).
Number of subjects: 11
Study 34821105 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tangeretin orally for 4 weeks
Number of subjects: 24
Study 34821105 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 24
Study 35316078 — intervention group
Group type: EXPERIMENTAL
Intervention: UMP in modified flank free supine position (Group A)
Number of subjects: 122
Study 35316078 — intervention group
Group type: COMPARATOR
Intervention: UMP in prone position (Group B)
Number of subjects: 122
Study 35912663 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial management intervention for people with HIV who are experiencing homelessness or housing instability
Number of subjects: 0
Study 35912663 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-engaged approach to restarting research
Number of subjects: 0
Study 35912663 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 policies and procedures developed for BAO
Number of subjects: 0
Study 32567679 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 84
Study 32567679 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (END)
Number of subjects: 84
Study 35901954 — intervention group
Group type: EXPERIMENTAL
Intervention: PIP 10 cmH2O
Number of subjects: 108
Study 35901954 — intervention group
Group type: EXPERIMENTAL
Intervention: PIP 15 cmH2O
Number of subjects: 108
Study 35901954 — intervention group
Group type: EXPERIMENTAL
Intervention: PIP 20 cmH2O
Number of subjects: 108
Study 33115783 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch and/or polydextrose (PD) supplementation for 50 days
Number of subjects: 75
Study 33115783 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (PD) supplementation
Number of subjects: 75
Study 33115783 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher E‐DII scores
Number of subjects: 75
Study 32951708 — intervention group
Group type: EXPERIMENTAL
Intervention: Eugenol nanoemulsion gel 4%
Number of subjects: 68
Study 32951708 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 68
Study 35144947 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Energy Planning (PEP) programme, a tailored, web‐supported 7‐9 weeks energy management programme
Number of subjects: 30
Study 35144947 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Energy Planning (PEP) programme
Number of subjects: 30
Study 35144947 — intervention group
Group type: COMPARATOR
Intervention: Attention control (general disease self‐management education)
Number of subjects: 30
Study 33568616 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp group (n = 24)
Number of subjects: 43
Study 33568616 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 43
Study 34133061 — intervention group
Group type: EXPERIMENTAL
Intervention: In-center nocturnal hemodialysis (INHD)
Number of subjects: 36
Study 34133061 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 36
Study 33418336 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS) and Methotrexate (MTX)
Number of subjects: 128
Study 33418336 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 128
Study 35964610 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (40 mg for 6–11 years; 100 mg for 12–17 years)
Number of subjects: 290
Study 35964610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 35964610 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 290
Study 33090083 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Intervention (GI)
Number of subjects: 125
Study 33090083 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Intervention (II)
Number of subjects: 125
Study 33090083 — intervention group
Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 125
Study 35768897 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist Position Sense Test (WPST) treatment group (n=10)
Number of subjects: 28
Study 35768897 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=7)
Number of subjects: 28
Study 35768897 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist Position Sense Test (WPST) in children with CP
Number of subjects: 28
Study 35768897 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist Position Sense Test (WPST)
Number of subjects: 28
Study 33719505 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip treatment
Number of subjects: 614
Study 33719505 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy alone
Number of subjects: 614
Study 32952830 — intervention group
Group type: EXPERIMENTAL
Intervention: 400μg sublingual Misoprostol
Number of subjects: 211
Study 32952830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 35728797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 35728797 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU/day vitamin D
Number of subjects: 73
Study 35728797 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin D
Number of subjects: 73
Study 34399765 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of amenities in parks
Number of subjects: 0
Study 34399765 — intervention group
Group type: EXPERIMENTAL
Intervention: Diversity of active facilities in parks
Number of subjects: 0
Study 34399765 — intervention group
Group type: EXPERIMENTAL
Intervention: Greenness of parks
Number of subjects: 0
Study 34399765 — intervention group
Group type: EXPERIMENTAL
Intervention: Park safety in low-income neighbourhoods
Number of subjects: 0
Study 34399765 — intervention group
Group type: EXPERIMENTAL
Intervention: Park safety in high-income neighbourhoods
Number of subjects: 0
Study 34399765 — intervention group
Group type: EXPERIMENTAL
Intervention: Park aesthetics in low-income neighbourhoods
Number of subjects: 0
Study 34399765 — intervention group
Group type: EXPERIMENTAL
Intervention: Park aesthetics in high-income neighbourhoods
Number of subjects: 0
Study 35034125 — intervention group
Group type: EXPERIMENTAL
Intervention: Target and distractor stimuli (differing in color)
Number of subjects: 0
Study 35034125 — intervention group
Group type: COMPARATOR
Intervention: Task‐irrelevant filler stimuli (having a third color)
Number of subjects: 0
Study 32129145 — intervention group
Group type: EXPERIMENTAL
Intervention: Achillon
Number of subjects: 114
Study 32129145 — intervention group
Group type: EXPERIMENTAL
Intervention: MMIR
Number of subjects: 114
Study 36384662 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg subcutaneous every 2 weeks)
Number of subjects: 28
Study 36384662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 33742240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone premedication (8 mg/twice daily for 3 days) followed by tapering dexamethasone (4 mg/daily for 2 days followed by 2 mg/daily for 2 days)
Number of subjects: 130
Study 33742240 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone premedication (8 mg/twice daily for 3 days)
Number of subjects: 130
Study 32367340 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/rosuvastatin 10/5 mg
Number of subjects: 50
Study 32367340 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 20 mg
Number of subjects: 50
Study 35729758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) (∼25 g CHO/d)
Number of subjects: 8
Study 35729758 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate diet (CHO) (∼285 g CHO/d)
Number of subjects: 8
Study 35729758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 8
Study 34112100 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical estrogen
Number of subjects: 195